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Abstract: Cancer patients frequently suffer from fatigue, a complex 
syndrome associated with tiredness and depressed mood. Cancer-related 
fatigue (CRF) can be present at the time of diagnosis, escalates during 
treatment, and can persist for years after treatment. CRF negatively 
influences quality of life, limits functional independence, and is associated 
with decreased survival in patients with incurable disease. We have previously 
shown that increased pro-inflammatory cytokine expression in the brain 
contributes to depressive- and fatigue- like behaviors in a mouse model of 
CRF. Inflammatory cytokines increase activity of indoleamine 2,3-dioxygenase 
(IDO) and kynurenine 3-monooxygenase (KMO), which competitively reduce 
serotonin synthesis. Reduced serotonin availability in the brain and increased 
production of alternative neuroactive metabolites of tryptophan are thought to 
contribute to the development of depression and fatigue. The purpose of this 
study was to determine the effects of fluoxetine, a selective serotonin 
reuptake inhibitor (SSRI), on brain cytokines and behavioral measures of 
fatigue and depression in tumor-bearing mice. Here we show that tumor 
growth increased brain expression of pro-inflammatory cytokines and KMO. 
Treatment with fluoxetine had no effect on tumor growth, muscle wasting, 
fatigue behavior, or cytokine expression in the brain. Fluoxetine, however, 
reduced depressive-like behaviors in tumor bearing mice. In conclusion, our 
data confirm that increased brain expression of pro-inflammatory cytokines is 
associated with tumor-induced fatigue and depressive-like behavior. However, 
it is possible to separate the effects of tumor growth on mood and fatigue-like 
behaviors using SSRI’s such as fluoxetine. 
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1. Introduction 
Cancer related fatigue (CRF) is the most common and most 
distressing symptom reported by cancer patients. CRF is characterized 
by overwhelming tiredness and lack of energy which significantly 
reduce quality of life.1 Importantly, fatigue is reported by cancer 
patients before and during treatment, and can continue for years after 
completion of treatment.2–4 In addition, CRF is frequently associated 
with depressed mood,5–7 although the mechanism for this association 
is unclear. A recent report8 suggests that pre-existing psychological 
conditions, such as depressed mood, increase the risk of persistent 
fatigue after completion of treatment. Others reported that treatment 
of cancer patients with antidepressant medications, such as selective 
serotonin reuptake inhibitors (SSRI), during chemotherapy improved 
mood but did not affect patient reports of fatigue.9, 10 Others found 
that treatment with modafinil improved fatigue, but not depression, in 
cancer patients during chemotherapy.11 
The association between symptoms of depression and fatigue in 
cancer patients suggests a common pathological pathway. Mounting 
evidence from both clinical and preclinical studies indicates that 
elevations in pro-inflammatory cytokines may function as a common 
mechanism for the frequent association of fatigue and depression in 
patients with CRF. For instance, elevated serum levels of pro-
inflammatory cytokines, such as tumor necrosis factor-alpha (TNFα), 
interleukin (IL)-1β and IL-6, are associated with fatigue in cancer 
patients.12, 13 Increases in systemic inflammation are relayed to the 
brain where inflammation is propagated by innate immune cells.14 
Increased neuroinflammation, for example increased brain IL-1β 
expression, has been linked to both depressed mood15 and fatigue.16 
Using a mouse model of CRF, we have previously shown that increased 
expression of pro-inflammatory cytokines within the CNS is associated 
with behavioral measures of fatigue, such as decreased voluntary 
wheel running (VWRA) activity, measures of weakness, such as 
reduced grip strength, and depressed mood, such as immobility during 
the forced swim test (FST) and anhedonia.17 Treatment with 
minocycline, a drug that reduces brain synthesis of inflammatory 
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cytokines, reduced depressive-like behaviors and improved grip 
strength in tumor-bearing mice.17 
There are several proposed mechanisms by which increased 
neuroinflammation can lead to altered mood. Inflammatory cytokines 
increase expression and activity of the tryptophan degrading enzymes 
indoleamine 2,3-dioxygenase (IDO) and kynurenine 3-monooxygenase 
(KMO), which competitively inhibits activity of tryptophan hydroxylase 
(TPH) for metabolism of tryptophan to serotonin. Increased tryptophan 
metabolism by IDO into neuroactive metabolites leads to an imbalance 
in serotonin neurotransmission and subsequent development of 
depression.18, 19 Inflammatory cytokines also increase expression and 
activity of the serotonin transporter.20 A recent study showed that 
peripheral tumors altered serotonin signaling pathways and decreased 
overall serotonin levels in the hypothalamus of tumor bearing mice.21 
The purpose of the present study was to examine the effect of 
fluoxetine, a selective serotonin reuptake inhibitor (SSRI), on brain 
expression of pro-inflammatory cytokines and behaviors of fatigue and 
depressed mood in tumor bearing mice. 
2. Materials and methods 
2.1 Mice 
Adult (10 weeks) female BALB/c×DBA/2 F1 (CD2F1) mice 
weighing 20–22 g were obtained from Charles River Laboratories. 
Female mice were used because we and others have shown that 
tumor-bearing females maintain their food intake longer and lose a 
smaller percent of body mass than male mice22 and male mice tend to 
gnaw and bite at the tumor site more than females, causing local 
inflammation.23 Mice were singly housed and maintained at 25°C 
under a 12 h light cycle with ad libitum access to water and rodent 
chow. All procedures were performed in accordance with the National 
Institute of Health Guidelines for the Care and Use of Laboratory 
Animals and were approved by The Ohio State University Institutional 
Animal Care and Use Committee. 
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2.2 Mouse model of tumor-growth 
The colon26 adenocarcinoma (colon26) cell line was maintained 
in culture and prepared for injection as previously described.24 Mice 
were injected subcutaneously between the scapulae with 5×105 cells in 
0.2 ml of PBS or PBS alone. This tumor cell line is syngeneic for CD2F1 
mice and secretes IL-6 and TNF-α25 and does not metastasize when 
injected subcutaneously.26 Tumor growth is usually palpable by day 7; 
weight loss, splenomegaly, and muscle wasting are evident after day 
14, and mice become moribund by day 24 of tumor-growth. In the 
present study, all data collection was completed by day 21 of tumor 
growth. Body weight was monitored three times a week for the first 
two weeks, and daily during the third week. Mice were euthanized by 
inhalation of CO2 gas on day 21 of tumor growth. Gastrocnemius 
muscles, spleen, and tumor were dissected and weighed; the brain 
was quickly dissected and hippocampus brain tissue was snap frozen in 
liquid nitrogen. Carcass weight was determined by subtracting tumor 
weight from body weight at the time of sacrifice. 
2.3 Oral Fluoxetine administration 
Fluoxetine (Sigma, St. Louis) was administered in the drinking 
water at a dose of 3 mg/kg/day (Sigma, St. Louis) starting one day 
after injection of PBS or tumor cells. This dose of fluoxetine has 
previously been shown to block depressive-like behavior in mice 
without affecting locomotor activity of healthy mice.27 Water intake 
was monitored every other day. There was no difference between fluid 
intakes during the first two weeks of tumor growth. During week 
three, both tumor groups had increased water intake, but there was 
no difference between water and fluoxetine intake in the tumor 
animals. Water bottles were changed weekly throughout the study. 
Fluoxetine diluted in water has previously been shown to be stable for 
8 weeks at room temperature.28 
2.4 Voluntary wheel running activity 
Fatigue-like behavior was determined using voluntary wheel 
running activity (VWRA).29 Mice were singly housed and acclimated to 
a four inch diameter running wheel in the cage for one week, and 
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baseline measures (week 0) of VWRA were recorded overnight prior to 
injection with tumor cells or PBS. Wheels were again placed in the 
home cages of all mice overnight (6 p.m. to 8 a.m.) on days 8 (week 
1), 14 (week 2) and 19 (week 3) of tumor growth and the total 
number of turns each night was digitally recorded (Columbus 
Instruments, model 0297-004M). 
2.5 Home cage locomotor activity 
Home cage locomotor activity test was performed between 
4:30–6pm, before the beginning of the dark cycle when mice become 
more active and there is minimal disturbance in the vivarium. Mice 
were maintained in their home cage with a floor area of 26×20 cm, 
and activity was video recorded for 3 minutes. On the video records, 
cages were divided into 6 identical virtual rectangles and the number 
of line crossings was determined. 
2.6 Depressive-like behavior 
Depressive-like behavior was determined on day 13 using the 
forced swim test (FST) as described previously.30 The FST was 
performed following the home cage locomotor test between 4:30–
6pm. Mice were placed in an inescapable cylinder (diameter 16 cm, 
height 30 cm) containing 15 cm of water and behavior was recorded 
for five min. The latency to become immobile and the duration of 
immobility were determined. 
2.7 RNA isolation and RT-PCR analysis 
RNA was isolated from hippocampus brain sections using the 
Tri-Reagent protocol (Sigma) and reverse transcribed to cDNA using 
the High Capacity cDNA Reverse Transcription kit (Applied 
Biosystems). Quantitative PCR was performed using the Applied 
Biosystems Assay-on-Demand Gene Expression protocol. In brief, 
experimental cDNA was amplified with an ABI PRISM 7300-sequence 
detection system (Applied Biosystems) by real-time PCR and 
normalized based on reference cDNA (GAPDH). Data were analyzed 
with the comparative threshold cycle method. Data is expressed as 
fold change from control-vehicle. 
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2.8 Statistical Analysis 
Data were subjected to a Shapiro-Wilk test using Statistical 
Analysis Systems (SAS) software (Cary, NC). Observations greater 
than three interquartile ranges from the first and third quartile were 
considered outliers and were excluded in the subsequent analyses. To 
determine significant main effects and interactions between main 
factors, data were analyzed using one- or two- way ANOVA using the 
General Linear Model procedures of SAS. Differences between group 
means were evaluated with the t-test using the Least-Significant 
Difference procedure of SAS. All data are expressed as treatment 
means ± standard error of the mean (SEM). 
3. Results 
3.1 Effects of fluoxetine on tumor growth 
Mice were treated with water (vehicle) or fluoxetine at 
3mg/kg/day starting at one day after tumor cell inoculation to the 
completion of the study. In this model, tumor bearing mice lose 
significant muscle mass with the progression of tumor growth. Fig. 1A 
shows total body weight throughout the study. At the completion of 
the study (Day 21) tumor bearing mice had significantly decreased 
carcass weight compared to healthy control mice (Fig.1B) 
(F1,52=31.70, p<0.0001). There was no effect of fluoxetine on carcass 
weight. Associated with decreased carcass weight, gastrocnemius 
muscle mass was decreased in tumor-bearing mice compared to 
healthy controls (F1,52=147.86, p<0.0001) and was not altered by 
fluoxetine treatment (Fig.1C). Fluoxetine treatment had no effect on 
tumor mass (Fig.1D) or spleen weight, a nonspecific measure of 
systemic inflammation (Fig.1E). These data confirm that fluoxetine had 
no effects on tumor growth, weight loss, or loss of muscle mass in the 
tumor-bearing mice. 
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Figure 1. Fluoxetine had no effect on tumor growth 
Control and tumor-bearing mice were administered fluoxetine (3mg/kg/day) in the 
drinking water starting one day after tumor cell injection. A) Body weight was 
monitored through the study. At the completion of the study, B) carcass weight, C) 
gastrocnemius muscle mass, D) tumor mass, and E) spleen weight (n=12) were 
analyzed using ANOVA. Means with * are different from control mice (p<0.05). 
3.2 Effects of fluoxetine on tumor-induced fatigue 
In this experiment, fatigue was modeled as a reduction in 
VWRA.29 VWRA progressively declined starting at day 14 in tumor-
bearing mice (F1,38=48.33, p<0.0001) and there was no effect of 
fluoxetine on VWRA (Fig.2). 
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Figure 2. Fluoxetine had no effect on tumor-associated fatigue 
Control and tumor-bearing mice were administered fluoxetine (3mg/kg/day) in the 
drinking water starting one day after tumor cell injection. Voluntary wheel running 
activity (VWRA) was determined before tumor cell inoculation and again overnight on 
days 8, 14 and 19 (n=12). Data are expressed as mean ± SEM and analyzed using 
ANOVA. Means with * are different from control mice (p<0.05). 
3.3 Effects of fluoxetine on tumor-induced depressive-
like behavior 
Depressive-like behavior was determined at 13 days after tumor 
cell inoculation using the forced swim test (FST). Fig. 3A shows that 
home cage locomotor activity was not different between any of the 
groups, indicating that tumor bearing mice did not exhibit lethargy. 
Fig. 3B&C show that tumor bearing mice became immobile sooner 
than healthy control mice (F1,51=11.66, p<0.0013), and had increased 
total time immobile in the FST (p<0.01). Tumor bearing mice treated 
with fluoxetine, however, had decreased time to become immobile 
(F1,51=9.90, p<0.0029) and also decreased total time immobile 
(F1,52=6.48, p<0.014) compared to tumor mice that were not treated 
with fluoxetine. There were no significant differences between tumor 
bearing mice treated with fluoxetine and control mice. This dose of 
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fluoxetine had no effect on locomotor activity or immobility during the 
FST in healthy control mice, as was reported by others.31 
 
Figure 3. Fluoxetine inhibited depressive-like behavior in tumor bearing mice 
Control and tumor-bearing mice were administered fluoxetine in the drinking water 
starting one day after tumor cell injection. A) Home cage activity was determined 13 
days after tumor inoculation. Control and tumor mice were exposed to the forced swim 
test (FST) at 13 days and B) latency to become immobile and C) total time immobile 
(n=12) were analyzed using ANOVA. Bars represent the mean ± SEM. Means with * 
are different from control (p<0.05). 
3.4 Expression of brain cytokine mRNA 
In a previous report, we demonstrated that tumor growth 
increased IL-1β and IL-6 mRNA expression in the hippocampus at 2 
weeks of tumor growth and that expression levels were further 
increased by 3 weeks.17 In the present study, cytokine expression was 
determined in the hippocampus at day 21 (week 3). By 21 days of 
tumor growth, expression of IL-1β and IL-6 was increased in tumor 
bearing mice compared to healthy controls (Fig.4A&B) (F1,27=10.71, 
p<0.003). Fluoxetine administration had no effect on IL-1β or IL-6 
mRNA expression in the hippocampus. Fluoxetine, however, tended to 
reduce the expression of TNFα in both tumor-bearing and healthy 
control mice (Fig.4C) (F1,28=3.66, p=0.06). There was a tendency for 
KMO expression to be increased at 21 days of tumor growth 
(F1,26=2.59, p=0.1), and there was no effect of fluoxetine on KMO 
mRNA (Fig.4D). IDO expression was not altered with tumor growth or 
fluoxetine administration (data not shown). 
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Figure 4. Fluoxetine had no effect on tumor-induced pro-inflammatory cytokine 
expression in the hippocampus 
Control and tumor-bearing mice were administered fluoxetine (3mg/kg/day) in the 
drinking water. A–D) IL-1β, IL-6, TNFα, and KMO mRNA expression was determined in 
the hippocampus at 21 days (n=6–8). Data are expressed as mean ± SEM and were 
analyzed using ANOVA. Means with * are different from control mice (p<0.05), means 
with + tend to be different from control mice (p=0.1). 
In conclusion, fluoxetine had no effect on tumor size, muscle 
mass, inflammatory cytokine expression in the brain, or fatigue 
behavior, but ameliorated depressive-like behavior in the tumor-
bearing mice. 
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4. Discussion 
Fatigue is a common and distressing symptom reported by 
cancer patients before, during, and after cancer treatments. 
Depressive symptoms are prevalent in patients with CRF and are 
associated with higher mortality rates in patients with persistent or 
incurable disease.32, 33 Therefore, treatments to reduce fatigue and 
depression in cancer patients are needed to increase quality of life and 
perhaps prolong survival. In this study, a mouse model of CRF was 
used to determine the effects of fluoxetine, a SSRI, on behavioral 
measures of depression and fatigue in tumor bearing mice. Here we 
report that tumor-bearing mice demonstrate fatigue (decreased 
VWRA) and depressed mood (increased immobility in FST) before 
weight loss is evident. We have previously shown that fatigue and 
depressive-like behavior in tumor-bearing mice is associated with 
increased expression of IL-1β and IL-6 in the cortex and hippocampus, 
brain regions associated with mood and motor activity.17 Treatment of 
the tumor-bearing mice with fluoxetine did not affect tumor growth, 
body weight, muscle mass, or cytokine expression in the brain. 
However, fluoxetine reduced tumor-induced depressive-like behavior 
in tumor-bearing mice. These findings explain in part previous reports 
that treatment with an SSRI reduced depression, but did not reduce 
fatigue in cancer patients undergoing chemotherapy.9, 10 
Reduced VWRA is used to model fatigue in rodents in response 
to immune challenge34 or chemotherapy.29 Consistent with our 
previous study,17 we show that VWRA progressively decreases in 
tumor bearing mice after day 14 of tumor growth with no change in 
home cage locomotor activity. These findings indicate that tumor 
growth did not cause general malaise or lethargy. Consistent with 
clinical findings,9, 10 treatment with fluoxetine, a SSRI, did not affect 
fatigue behavior in tumor-bearing mice. 
Depression often co-occurs with fatigue and is frequently 
reported by patients undergoing chemotherapy.7 In our mouse model 
of CRF, tumor-bearing mice demonstrated depressive-like behavior in 
the FST. We have previously shown that the increase in immobility in 
the FST is not due to changes in muscle function, lethargy, or 
malaise.17 Here we show that treatment with 3/mg/kg/day fluoxetine 
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was sufficient to ameliorate depressive-like behavior in tumor-bearing 
mice without changing mood-related behavior in healthy control 
mice.31 Fluoxetine treatment had no effect on muscle mass, VWRA, or 
home cage locomotor activity in tumor-bearing mice. These data 
suggest the effects of fluoxetine were specific to tumor-induced 
depressive-like behavior in these mice. 
The underlying mechanisms of CRF are unknown but may be 
related to a heightened inflammatory state.2 In rodent models of 
inflammation and immune activation, elevated IL-1β expression in the 
brain has been associated with fatigue and depression.16, 30 The results 
of the present study support the hypothesis that tumor growth induces 
neuroinflammation, which negatively affects mood which may play a 
major role in the association of fatigue and depression in cancer 
patients.4–6, 35, 36 
Previous studies have shown anti-inflammatory effects of 
fluoxetine on neuroinflammation. For example, fluoxetine decreased 
TNFα and IL-1β expression in a rat model of stroke.37 In our study, we 
show that peripheral inflammation (spleen weight) was not affected by 
fluoxetine treatment, nor was brain expression of IL-1β and IL-6 
mRNA. As shown in our previous study17 growth of this tumor did not 
increase brain expression of TNFα mRNA; however, fluoxetine reduced 
TNFα expression in the brain of both tumor-bearing and control mice. 
Previous studies has shown that 5 mg/kg fluoxetine treatment 
decreased plasma TNFα in mice injected with lipopolysaccharide38 and 
reduced TNFα expression in immune activated microglia and monocyte 
cell lines.39 It is possible that TNFα is a specific regulatory target of 
fluoxetine treatment. It is also possible that administration of a higher 
dose of fluoxetine may alter pro-inflammatory cytokine expression in 
the brain. However, high doses of fluoxetine alter locomotor activity 
which might confound our measures of home cage activity and VWRA 
in the treated animals.27 Therefore we chose to use a relatively low 
dose of fluoxetine in the present study. Overall, the reduced 
depressive-like behavior in tumor bearing mice treated with fluoxetine 
was not due to reduced expression of IL-1β, IL-6, IDO or KMO mRNA 
in the brain of treated mice. We hypothesize that fluoxetine enhanced 
serotonin activity in the brain without changing tumor-induced 
neuroinflammation. 
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Peripheral and CNS inflammation are also thought to induce 
depressive-like behavior via increased activity of IDO and KMO, which 
may reduce serotonin synthesis in the brain. Because pro-
inflammatory cytokines can increase expression and activity of the IDO 
enzyme40 and serotonin transporter,20 we suggest a link between 
increased pro-inflammatory cytokines and decreased serotonin 
availability in the tumor bearing mice. We and others have shown that 
inhibiting IDO activity decreases serotonin turnover in the brain.40–42 
As an SSRI, fluoxetine treatment reduces serotonin reuptake into the 
presynaptic cell, which increases extracellular levels of serotonin in the 
synaptic cleft that is available to bind to the postsynaptic receptor. 
Tryptophan is the limiting factor for the synthesis of serotonin, 
therefore, increased activity of IDO may alter serotonin availability and 
turnover. In this study we show novel data that KMO expression was 
greater in tumor-bearing mice than in control mice, which suggests 
that tryptophan is shunted into the IDO and KMO-mediated pathway of 
tryptophan metabolism. Previous studies showed that peripheral tumor 
progression decreased serotonin levels in the hypothalamus of tumor 
bearing mice.21, 43 Therefore, it is likely that altered serotonin 
availability contributes to depressed mood associated with tumor 
growth. Prior reports that SSRIs reduce depression in cancer 
patients,9, 10 and our finding that fluoxetine inhibited depression-like 
behavior in tumor bearing mice support this hypothesis. Further 
research using methods such as microdialysis to determine free 
serotonin in the cerebrospinal fluid of treated versus untreated tumor-
bearing mice is needed to confirm this hypothesis. Other explanations 
for the beneficial effects of fluoxetine include improved neuronal 
plasticity and neurogenesis. Recent studies using rodent models have 
shown that neurogenesis is decreased in the hippocampus of tumor 
bearing mice.23 In a model of chemotherapy, fluoxetine treatment 
increased hippocampal neurogenesis and rescued memory 
impairments induced by the chemotherapy treatment.44 Further 
research is needed to determine if fluoxetine affected hippocampal 
neurogenesis in our study, which may have played a role in reducing 
depressive-like behaviors. 
In conclusion, we show that a low dose (3mg/kg/day) of 
fluoxetine administration is sufficient to reduce depressive-like 
behaviors in tumor-bearing mice without altering other physiological 
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effects of tumor growth. Consistent with clinical studies, fluoxetine had 
no effect on tumor-induced fatigue behaviors in this animal model of 
CRF. These data suggest that fatigue and depression associated with 
CRF may be treated as two distinct symptoms. 
Highlights 
Tumor growth increased brain expression of pro-inflammatory 
cytokines. 
Fluoxetine had no effect on cytokine expression in tumor bearing mice. 
Fluoxetine reduced depressive-like behaviors but not fatigue in tumor 
bearing mice. 
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